SOTIO Doses First Patient In Phase 1 Study Of SOT201 For Solid Tumors
Details : SOT201, a next-generation PD-1-targeting immunocytokine monotherapy being investgated for the treatment of advanced solid tumors.
Product Name : SOT201
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 28, 2024
Details : SOT102 is a CLDN18.2 targeting highly specific mAB conjugated to a potent cytotoxic drug molecule, Preclinical data from studies of SOT102 have demonstrated potent anti-tumor efficacy in vitro and in vivo due to NBE’s proprietary site-specific SMAC con...
Product Name : SOT102
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, SOTIO will conduct a Phase 2 open-label, multicenter study of SOT101 in combination with KEYTRUDA to evaluate efficacy and safety in patients with selected advanced or refractory solid tumors.
Product Name : SO-C101
Product Type : Protein
Upfront Cash : Undisclosed
August 12, 2021
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : PPF Group
Deal Size : $316.5 million
Deal Type : Financing
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
Details : The funding will be used for SOT101 clinical trials: The phase 2 AURELIO-03 study tests SOT101 as monotherapy in patients with melanoma, squamous skin carcinoma and kidney cancer, and phase 2 AURELIO-04 study will evaluate the combination of SOT101 with ...
Product Name : SO-C101
Product Type : Protein
Upfront Cash : Undisclosed
February 12, 2021
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : PPF Group
Deal Size : $316.5 million
Deal Type : Financing
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary efficacy signal, with a confirmed partial response observed after SO-C101 monotherapy in a patient with skin squamous cell carcinoma refractory to anti-PD-1 therapy.
Product Name : SO-C101
Product Type : Protein
Upfront Cash : Inapplicable
November 11, 2020
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Cytune Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SOTIO announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors.
Product Name : SO-C101
Product Type : Protein
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Cytune Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Cytune Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors.
Product Name : SO-C101
Product Type : Protein
Upfront Cash : Inapplicable
April 11, 2020
Lead Product(s) : SO-C101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Cytune Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable